Abstract Library

#2826 NET-02: A Phase II Trial of Liposomal Irinotecan (nal-IRI) and 5-Fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-Line Therapy in Patients (pts) with Progressive Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma (PD-EP-NEC)

Introduction: The prognosis for pts with PD-EP-NEC is poor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: McNamara M

Authors: McNamara M, Swain J, Craig Z, Wadsley J, Wall L,

Keywords: poorly differentiated, neuroendocrine carcinoma, second line treatment, docetaxel, liposomal irinotecan, 5-fluorouracil,

#1778 Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?

Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Derks J

Authors: Derks J, Suylen R, Thunnissen E, Den Bakker M, Groen H,

Keywords: lcnec, chemotherapy, nec, lung,

#64 Sustained response to anti IGFR-1R monoclonal antibody combined with docetaxel in a patient with metastatic adrenocortical carcinoma

Introduction: Adrenocortical carcinoma (ACC) is a rare neoplasm with poor prognosis. Treatment results in advanced disease are disappointing and median survival is less than 12 months. There is no standard chemotherapy, even though mitotane and cisplatin-based regimens are frequently used with limited efficacy. In vitro data suggest that overexpressed insulin growth factor-2 (IGF-2) acting via the IGF-1 receptor (IGF-1R) is relevant for ACC and that the IGF-1R and 2R pathway is a promising target.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: De Dosso S, Saletti P, Gallerani E, Terrot T, Sessa C,

Keywords: adrenocortical carcinoma, anti IGFR-1R monoclonal antibody,